文献速递胸部肿瘤

达克替尼获得性耐药机制:EGFR T790M与C797S突变

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
PubMed 文献 · J Thorac Oncol · 2018-02-02

本研究在体外建立达克替尼耐药克隆,探讨其获得性耐药机制。结果显示达克替尼可直接诱导T790M或C797S二次突变,且不同突变对后续EGFR抑制剂敏感性不同,提示分析二次突变有助于选择合适EGFR抑制剂。

要点

  • 达克替尼体外可诱导EGFR T790M或C797S二次突变。
  • Del19/T790M细胞对奥希替尼敏感,L858R/C797S对吉非替尼或厄洛替尼敏感。
  • 获得性耐药后分析二次突变有助于选择EGFR抑制剂。

核心结论

  • 达克替尼在体外可直接诱导T790M或C797S二次突变,分析这些突变有助于克服耐药。

研究设计与样本

  • 体外研究,用ENU诱变或递增浓度达克替尼慢性暴露建立耐药克隆,Sanger测序分析EGFR二次突变。
  • 在Ba/F3细胞中引入Del19、L858R和G719A突变,比较不同突变状态下的耐药时间。

主要发现

  • 无ENU慢性暴露达克替尼在表达Del19的Ba/F3细胞中诱导T790M。
  • ENU诱变获得171个达克替尼耐药克隆,其中90%获得T790M。
  • 低剂量达克替尼建立的L858R突变克隆中C797S发生率为11%(4/35),G719A突变克隆中为24%(12/38)。
  • T790M与C797S突变克隆的耐药时间在L858R克隆(p=0.93)和G719A克隆(p=0.86)中均无显著差异。
  • 表达Del19并获得T790M的细胞对奥希替尼敏感,而L858R加C797S突变细胞对吉非替尼或厄洛替尼敏感。

临床怎么用

  • 达克替尼耐药后应分析EGFR T790M和C797S等二次突变,以指导后续EGFR抑制剂选择。

局限性

  • 研究为体外实验,结论需临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Dacomitinib was superior to gefitinib in terms of progression-free survival in patients with EGFR-mutant lung cancer in a recent ARCHER 1050 trial. However, despite a marked initial response, lung cancers eventually acquire resistance to these inhibitors. This study aimed to elucidate the mechanisms of acquired resistance to dacomitinib in vitro. METHODS: Dacomitinib-resistant clones were established by exposure to fixed concentrations of dacomitinib by using N-ethyl-N-nitrosourea (ENU) mutagenesis or by chronic exposure to increasing concentrations of dacomitinib without ENU. EGFR secondary mutations were analyzed by Sanger sequencing. Time to resistance in each clone was compared according to the mutational status. EGFR Del19, L858R, and G719A mutations were introduced into Ba/F3 cells by using retroviral vectors. RESULTS: Chronic exposure to dacomitinib without ENU induced T790M in Ba/F3 cells expressing Del19. ENU mutagenesis resulted in 171 dacomitinib-resistant clones. Among these clones, 90% acquired T790M. However, C797S occurred in 11% of L858R-mutant clones (four of 35) and in 24% of G719A-mutant clones (12 of 38) established by using low-dose dacomitinib. Time to resistance was not significantly different between T790M- and C797S-mutant clones in both of L858R clones (p = 0.93) and G719A clones (p = 0.86). Cells expressing Del19 that acquired T790M were sensitive to osimertinib, whereas cells with L858R plus C797S mutations were sensitive to gefitinib or erlotinib. CONCLUSIONS: These in vitro data demonstrate that dacomitinib can directly induce T790M or C797S secondary mutations. Our data suggest the importance of analyzing these secondary mutations because appropriate selection of EGFR inhibitors could overcome acquired resistance to dacomitinib in a subset of lung cancers.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kobayashi Y, Fujino T, Nishino M, et al. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib. J Thorac Oncol. 2018. PMID: 29410323. doi:10.1016/j.jtho.2018.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。